Management of osteoporosis in men: An update and case example

CMAJ. Canadian Medical Association Journal

Volumn 176, Issue 3, 2007, Pages 345-348

  Khan, Aliya A ^a   Hodsman, Anthony B ^b   Papaioannou, Alexandra ^a   Kendler, David ^c   Brown, Jacques P ^d   Olszynski, Wojciech P ^e  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITÉ LAVAL   (Canada)

^e UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CALCIUM CARBONATE; COLECALCIFEROL; ETIDRONIC ACID; GLUCOCORTICOID; PARATHYROID HORMONE[1-34]; PLACEBO; RISEDRONIC ACID; TESTOSTERONE;

BONE DENSITOMETRY; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG CONTRAINDICATION; DRUG USE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; MUSCLE CRAMP; NAUSEA; OSTEOPOROSIS; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; SPINE RADIOGRAPHY;

EID: 33846942671     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.050816     Document Type: Review

References (12)

1. Khan AA, Bachrach L, Brown JP, et al. Standards and guidelines for performing central dual-energy x-ray absorptiometry in premenopausal women, men, and children. J Clin Densitom 2004;7:51-64.
2. Jackson SA, Tenenhouse A, Robertson L. Vertebral fracture definition from population-based data: preliminary results from the Canadian Multicenter Osteoporosis Study (CaMos). Osteoporos Int 2000;11:680-7.
3. Johnell O, Kanis J, Gullber G. Mortality, morbidity and assessment of fracture risk in male osteoporosis. Calcif Tissue Int 2001;69:182-4.
4. Brown JP, Josse RG; Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada [review. Published errata in CAMJ 2003;18;168(4):400, 2003;18;168(5):544 and 2003;18;168(6):676]. CMAJ 2002;167(10 Suppl):S1-34.
5. Siminoski K, Leslie WD, Frame H, et al. Recommendations for bone mineral density reporting in Canada. Can Assoc Radiol J 2005;56:178-88.
6. Olszynski WP, Shawn DK, Adachi JD, et al. Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment. Clin Ther 2004;26:15-28.
7. Ringe JD, Faber H , Farahmand P, et al. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int 2006;26:427-31.
8. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998;339:292-9.
9. Reid D, Hughes R, Laan RF, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J Bone Miner Res 2000;15:1006-13.
10. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997;337:382-7.
11. Cranney A, Papaioannou A, Zytaruk N, et al. Parathyroid hormone for the treatment of osteoporosis: a systematic review. CMAJ 2006;175:52-9.
12. Hodsman A, Papaioannou A, Cranney A. Clinical practice guidelines for the use of parathyroid hormone in the treatment of osteoporosis. CMAJ 2006;175:52-0.